JNJ at a glance
Johnson & Johnson (JNJ, SEC CIK 200406) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 10, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), Johnson & Johnson (JNJ) reported revenue of $94.2 billion (up 6.0% from FY2024) and net income of $26.8 billion. Diluted EPS was $11.03.
- As of June 30, 2026, 74 institutional investment managers tracked by SignalX reported holding Johnson & Johnson (JNJ) shares worth $235.4 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Schmid Timothy on September 2, 2026 of 22,527 shares at $274.74 per share.
- In the last 90 days, JNJ insiders reported 0 open-market purchases ($0) and 10 open-market sales ($67.8M) on Form 4, a net sale of $67.8M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $94.2B
- +6.0% vs prior year
- Insiders · 90 days
- 0 buys · 10 sells
- Net −$67.8M
- 13F holders
- 74 funds
- $235.4B · +0 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 28, 2025
Business Overview
- Core business model not detailed; filing focuses on corporate governance and compliance policies
- New emphasis on transparency with online posting of Code of Business Conduct amendments and waivers within five business days
- Strengthened insider trading policy for directors, officers, and certain insiders to ensure compliance with laws and listing standards
- Unusual focus on detailed disclosure of corporate governance codes and ethical standards rather than product or market information
Management Discussion & Analysis
- Revenue $94.2B in 2025, up 6.0% YoY from $88.8B in 2024; U.S. sales $53.8B (+6.9%), international $40.4B (+5.0%)
- Operating margin 34.6% in 2025 vs 18.8% in 2024; Innovative Medicine margin 36.9% vs 33.2%; MedTech margin 12.2% vs 11.7%
- Best segment: Innovative Medicine sales $60.4B (+6.0%), worst: Infectious Diseases sales $3.2B (-4.6%)
- Cash/cash equivalents $20.1B end 2025; total debt $47.9B; acquisitions funded with senior notes; restructuring costs $205M (Surgery), $307M (Orthopaedics)
- Risks: biosimilar competition impacting STELARA; expected generic competition for OPSUMIT in 2026; planned Orthopaedics separation in 18-24 months
Risk Factors
- Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws
- CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry
- CIO and CISO responsible for cybersecurity incident detection, response, and recovery with 25+ years CISO experience
- Cybersecurity risk management integrated into overall risk framework, with emphasis on threats relevant to 2026 landscape
AI summary of the JNJ 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 28, 2026
Management Discussion & Analysis
- Q2 revenue $25.3B, up 6.6% YoY from $23.7B, with operational growth of 5.6%
- Q2 operating profitability 26.7% vs 27.3% YoY; segment margin 29.3% vs 28.5%
- Best segment Innovative Medicine revenue $16.4B, up 7.8%; worst MedTech margin 13.2% vs 14.1% YoY
- Cash, equivalents and current securities $20.8B vs $18.9B YoY; debt $49.0B vs $50.8B
- Headwinds: STELARA biosimilars, SIMPONI European competition and OPSUMIT U.S. generics likely reducing future sales
AI summary of the JNJ 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Jennifer Taubert retiring September 1, 2026 as Executive Vice President and Worldwide Chairman, Innovative Medicine
- Departure also removes Taubert from Johnson & Johnson’s Executive Committee
Item EX-99.1: Item EX-99.1
- Completed Firefly Bio acquisition for $1 billion cash, expanding J&J’s oncology platform into pan-KRAS and other difficult-to-treat cancers
- Firelink™ degrader antibody conjugate platform enables targeted protein degradation, supporting next-generation solid-tumor therapies
Item 7.01: Regulation FD Disclosure
- Firefly acquisition completed and Sail strategic collaboration signed, marking expanded investment in biotech pipeline
- 2026 adjusted EPS guidance reduced $0.64 to $10.96–$11.11, with transactions cutting adjusted operational EPS by $0.64
Item EX-99.1: Item EX-99.1
- Proposed $5.5B resolution for remaining ovarian talc claims, subject to participation representing at least 95% of claims
- First payment capped at $3B in 2027, with no additional payments due before 2028
Item 7.01: Regulation FD Disclosure
- $5.5B commitment to resolve ovarian talc litigation with leading plaintiff firms
- Settlement requires participation from at least 95% of remaining claims
AI summaries of JNJ 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for JNJ
Don't miss the next JNJ filing
- Alerts as it files. A push when JNJ files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut JNJ, by share count.
- Ask anything. An AI agent that reads every JNJ filing and answers with sources.
JNJ alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Woods Eugene A. | A | Sep 8, 2026 | 135.717 | $276.31 |
| Pinto Daniel E | A | Sep 8, 2026 | 113.098 | $276.31 |
| HEWSON MARILLYN A | A | Sep 8, 2026 | 180.956 | $276.31 |
| Schmid Timothy | M | Sep 2, 2026 | 11,070 | - |
| Schmid Timothy | Sell | Sep 2, 2026 | 22,527 | $274.74 |
| Schmid Timothy | M | Sep 2, 2026 | 22,527 | - |
| Schmid Timothy | Sell | Sep 2, 2026 | 11,070 | $274.74 |
| Schmid Timothy | M | Sep 2, 2026 | 22,527 | $151.41 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $88.8B | $94.2B |
| Gross Profit | $58.6B | $61.4B | $63.9B |
| Net Income | - | $14.1B | $26.8B |
| Gross Margin | - | 69.1% | 67.9% |
| Net Margin | - | 15.8% | 28.5% |
| Balance Sheet | |||
| Total Assets | $167.6B | $180.1B | $199.2B |
| Equity | - | $71.5B | $81.5B |
| ROE | - | 19.7% | 32.9% |
| Per Share | |||
| EPS | $13.72 | $5.79 | $11.03 |
| Cash Flow | |||
| Operating CF | $22.8B | $24.3B | $24.5B |
| CapEx | - | $4.4B | $4.8B |
Source: XBRL data in Johnson & Johnson (JNJ)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate JNJ share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 74 | $235.39B |
| Q1 2026 | 74 | $226.64B |
| Q4 2025 | 70 | $193.30B |
| Q3 2025 | 75 | $185.05B |
| Q2 2025 | 73 | $142.40B |
| Q1 2025 | 70 | $118.15B |
| Q4 2024 | 67 | $81.68B |
| Q3 2024 | 59 | $49.07B |
- T. Rowe Price Group+6.51M (+39%)
- Goldman Sachs Group+1.67M (+9%)
- Citigroup+1.09M (+39%)
- Vanguard Portfolio Management LLC+856.4K (+1%)
- Invesco Ltd+627.2K (+4%)
- JPMorgan Chase & Co−4.79M (-8%)
- FMR LLC (Fidelity)−2.18M (-9%)
- Bank of America Corp−2.08M (-8%)
- BlackRock−1.29M (-1%)
- AQR Capital Management−635.4K (-18%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 562 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
JNJ filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 4 | Aug 14, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 4 | Aug 7, 2026 | - | - | - |
| 13F-HR | Aug 6, 2026 | Jun 30, 2026 | - | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 8-K | Jul 29, 2026 | - | Analysis | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 10-Q | Jul 23, 2026 | Jun 28, 2026 | Analysis | |
| 4 | Jul 21, 2026 | - | - | - |
| 8-K | Jul 15, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 13F-HR | May 13, 2026 | Mar 31, 2026 | - | |
| 4 | May 4, 2026 | - | - | - |
| SC 13G | May 1, 2026 | - | - | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 4 | Apr 27, 2026 | - | - | - |
| 4 | Apr 27, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
JNJ SEC filings: frequently asked questions
Are JNJ insiders buying or selling?
In the last 90 days, Johnson & Johnson (JNJ) officers, directors and 10% owners reported no open-market purchases and 10 open-market sales worth $67.8 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold JNJ stock?
As of June 30, 2026, the largest Johnson & Johnson (JNJ) holders among the 13F filers tracked by SignalX were BlackRock ($53.9 billion), Vanguard Capital Management LLC ($39.9 billion), State Street Corp ($34.0 billion), Vanguard Portfolio Management LLC ($16.3 billion), JPMorgan Chase & Co ($15.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was JNJ's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), Johnson & Johnson (JNJ) reported revenue of $94.2 billion (up 6.0% from FY2024) and net income of $26.8 billion. Diluted EPS was $11.03. The figures come from the XBRL data in the 10-K.
What are the main risks in JNJ's latest 10-K?
In the 10-K filed February 11, 2026, Johnson & Johnson (JNJ) flagged: Board Regulatory Compliance & Sustainability Committee oversees cybersecurity risk and compliance with privacy laws. CISO provides quarterly updates on evolving cybersecurity threats and incidents impacting the company and industry. (AI summary of the Risk Factors section.)
What did JNJ report in its latest 8-K?
Johnson & Johnson (JNJ) filed an 8-K on August 4, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Jennifer Taubert retiring September 1, 2026 as Executive Vice President and Worldwide Chairman, Innovative Medicine.
What are the latest JNJ SEC filings?
Johnson & Johnson (JNJ) filed its latest 10-K annual report on February 11, 2026, a 10-Q quarterly report on July 23, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 10, 2026.
What is JNJ's SEC CIK number?
Johnson & Johnson (JNJ)'s SEC Central Index Key (CIK) is 200406. EDGAR lists every JNJ filing under that number.
Ask anything about JNJ
The research agent reads JNJ's filings, financials, insider trades and 13F holders, then answers with sources.